Search for a report

NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

  • You are here:
  • Home
  • Downloads
  • NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The North America non-alcoholic steatohepatitis (NASH) biomarker market is expected to grow with a CAGR of 20.02%, during the forecast years of 2021 to 2028. The region’s market growth is mainly attributable to the increasing prevalence of obesity and diabetes, the early diagnosis of NASH, the expected launch of pipeline molecules, and favorable reimbursements in the healthcare infrastructure. The North America non-alcoholic steatohepatitis (NASH) biomarker market growth is assessed by evaluating the United States and Canada.

NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

North America Non-alcoholic Steatohepatitis (Nash) Biomarker Market by Type (Serum Biomarker, Hepatic Fibrosis Biomarker, Apoptosis Biomarker, Oxidative Stress Biomarker, Other Types) by End-user (Pharma & Cro Industry, Diagnostic Lab, Academic Research Key, Hospital) and by Geography

Request free sample

The North America non-alcoholic steatohepatitis (NASH) biomarker market is expected to grow with a CAGR of 20.02%, during the forecast years of 2021 to 2028. The region’s market growth is mainly attributable to the increasing prevalence of obesity and diabetes, the early diagnosis of NASH, the expected launch of pipeline molecules, and favorable reimbursements in the healthcare infrastructure.

To learn more about this report, request a free sample copy

The North America non-alcoholic steatohepatitis (NASH) biomarker market growth is assessed by evaluating the United States and Canada. The incidence of non-alcoholic fatty liver diseases is primarily due to the increasing trend of obesity in the United States. Moreover, non-alcoholic fatty liver disease (steatohepatitis) is considered the most common type of chronic liver disease. As per the study conducted by the Intermountain Healthcare researchers, on the disease’s economic impact, the condition affects nearly 100 million Americans, annually. Likewise, its financial implications for the United States healthcare system accounts for at least $32 billion, each year.

On the other hand, according to Statistics Canada 2020, the rate of obesity in the country has increased by three times over the last 30 years. As a result, one in four Canadians is obese and is likely to need medical support in order to manage their condition. In addition to the obese population, the incidence of diabetes also observes a growing course in Canada. Hence, these factors are anticipated to fuel the non-alcoholic steatohepatitis (NASH) biomarker market growth in North America, during the forecast period.

Pfizer Inc, headquartered in the United States, is a biopharmaceutical company. It primarily discovers, manufactures, develops, and commercializes products such as, vaccines, medicines, as well as consumer healthcare products. The company provides its products for treating cardiovascular, respiratory, and metabolic diseases and conditions, cancer, inflammation, infection, and neurological problems, among others.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      •    KEY DRIVERS
        • GROWING NASH AFFECTED POPULATION
        • SURGING PREVALENCE OF OBESITY AND DIABETES
        • INCREASING OCCURRENCE OF CHRONIC DISEASES
        • SURGING AWARENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE
      •    KEY RESTRAINTS
        • SIDE-EFFECTS AND RISKS ASSOCIATED WITH NASH THERAPEUTICS
        • LACK OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    1. KEY ANALYTICS
      •    PORTER’S FIVE FORCES ANALYSIS
        • THREAT OF NEW ENTRY
        • THREAT OF SUBSTITUTION
        • BUYER’S POWER
        • SUPPLIER’S POWER
        • COMPETITIVE RIVALRY
      • IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY INVESTMENT INSIGHTS
    2. MARKET BY TYPE
      • SERUM BIOMARKER
      • HEPATIC FIBROSIS BIOMARKER
      • APOPTOSIS BIOMARKER
      • OXIDATIVE STRESS BIOMARKER
      • OTHER TYPES
    3. MARKET BY END-USER
      • PHARMA & CRO INDUSTRY
      • DIAGNOSTIC LAB
      • ACADEMIC RESEARCH KEY
      • HOSPITAL
    4. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • THE UNITED STATES
          • CANADA
    1. COMPETITIVE LANDSCAPE
      •    KEY STRATEGIC DEVELOPMENTS
        • MERGER & ACQUISITIONS
        • PRODUCT LAUNCH & DEVELOPMENTS
        • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
        • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
      •    COMPANY PROFILE
        • ALLERGAN PLC (ACQUIRED BY ABBVIE)
        • ASTRAZENECA
        • BRISTOL -MYERS SQUIBB COMPANY
        • GENFIT SA
        • GILEAD SCIENCES INC
        • MADRIGAL PHARMACEUTICALS
        • MERCK & CO
        • NOVARTIS AG
        • NOVO NORDISK
        • PFIZER INC
        • SIEMENS HEALTHINEERS
        • VIKING THERAPEUTICS
        • ZYDUS CADILA

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER

    TABLE 2: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 3: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 4: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 5: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 6: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 7: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 8: LEADING PLAYERS OPERATING IN NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

    LIST OF FIGURES

    FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 2: OPPORTUNITY MATRIX

    FIGURE 3: VENDOR LANDSCAPE

    FIGURE 4: KEY INVESTMENT INSIGHTS

    FIGURE 5: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020

    FIGURE 6: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)

    FIGURE 7: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)

    FIGURE 9: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020

    FIGURE 12: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)

    FIGURE 16: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

    FIGURE 17: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 18: CANADA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • THE UNITED STATES
          • CANADA
    1. MARKET BY TYPE
      • SERUM BIOMARKER
      • HEPATIC FIBROSIS BIOMARKER
      • APOPTOSIS BIOMARKER
      • OXIDATIVE STRESS BIOMARKER
      • OTHER TYPES
    2. MARKET BY END-USER
      • PHARMA & CRO INDUSTRY
      • DIAGNOSTIC LAB
      • ACADEMIC RESEARCH KEY
      • HOSPITAL

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now